Investors sold shares of Celgene Corp. (NASDAQ:CELG) on strength during trading hours on Friday. $102.76 million flowed into the stock on the tick-up and $176.19 million flowed out of the stock on the tick-down, for a money net flow of $73.43 million out of the stock. Of all companies tracked, Celgene Corp. had the 0th highest net out-flow for the day. Celgene Corp. traded up $0.93 for the day and closed at $112.19

CELG has been the topic of several recent research reports. Jefferies Group reaffirmed a “buy” rating and set a $138.00 target price on shares of Celgene Corp. in a report on Sunday, July 10th. Vetr lowered shares of Celgene Corp. from a “buy” rating to a “hold” rating and set a $106.06 target price on the stock. in a report on Wednesday, July 6th. JMP Securities reaffirmed a “buy” rating and set a $152.00 target price on shares of Celgene Corp. in a report on Wednesday, July 6th. Stifel Nicolaus initiated coverage on shares of Celgene Corp. in a report on Thursday, July 14th. They set a “buy” rating and a $138.00 target price on the stock. Finally, Credit Suisse Group AG reaffirmed an “outperform” rating and set a $140.00 target price on shares of Celgene Corp. in a report on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-two have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $136.93.

The stock has a market capitalization of $87.69 billion and a price-to-earnings ratio of 47.42. The firm’s 50 day moving average price is $102.41 and its 200-day moving average price is $103.04.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.05. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. Celgene Corp.’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.23 EPS. Equities research analysts predict that Celgene Corp. will post $5.74 earnings per share for the current year.

In other news, insider Robert J. Hugin sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 20th. The shares were sold at an average price of $100.16, for a total transaction of $7,512,000.00. Following the sale, the insider now owns 1,122,201 shares of the company’s stock, valued at approximately $112,399,652.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Several large investors have recently modified their holdings of the company. NBT Bank N A NY boosted its stake in shares of Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock worth $1,107,000 after buying an additional 30 shares during the last quarter. Twin Capital Management Inc. boosted its stake in shares of Celgene Corp. by 0.7% in the fourth quarter. Twin Capital Management Inc. now owns 23,890 shares of the biopharmaceutical company’s stock worth $2,861,000 after buying an additional 160 shares during the last quarter. Johnson Financial Group Inc. boosted its stake in shares of Celgene Corp. by 2.9% in the fourth quarter. Johnson Financial Group Inc. now owns 9,557 shares of the biopharmaceutical company’s stock worth $1,145,000 after buying an additional 266 shares during the last quarter. TrimTabs Asset Management LLC boosted its stake in shares of Celgene Corp. by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 17,614 shares of the biopharmaceutical company’s stock worth $2,109,000 after buying an additional 327 shares during the last quarter. Finally, Garcia Hamilton & Associates LP DE boosted its stake in shares of Celgene Corp. by 1.2% in the fourth quarter. Garcia Hamilton & Associates LP DE now owns 29,170 shares of the biopharmaceutical company’s stock worth $3,493,000 after buying an additional 346 shares during the last quarter.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.